Breast cancer
Results
Phase 2
This trial compared fulvestrant on its own with fulvestrant alongside either vistusertib or everolimus. It was for people with breast cancer that had come back after treatment or spread to another part of the body, and was oestrogen receptor positive.
Recruitment start: 1 April 2014
Recruitment end: 31 October 2016
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
AstraZeneca
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Queen Mary University of London
Last reviewed: 11 Feb 2019
CRUK internal database number: 11638
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
